Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA Wants Amended ANDAs To Trigger 30-Month Stays

Executive Summary

FDA should specify that ANDAs which change certification from Paragraph III to Paragraph IV should trigger for a 30-month stay, the Pharmaceutical Research & Manufacturers of America states in comments on FDA's proposed rule

You may also be interested in...



FDA Generics Rule: Agency Will Scrutinize Paragraph III Switches, Troy Says

Generic firms that switch Paragraph III patent certifications to Paragraph IVs once the threat of a 30-month stay of approval is gone will be subject to increased scrutiny by FDA, Chief Counsel Daniel Troy said

FDA Generics Rule: Agency Will Scrutinize Paragraph III Switches, Troy Says

Generic firms that switch Paragraph III patent certifications to Paragraph IVs once the threat of a 30-month stay of approval is gone will be subject to increased scrutiny by FDA, Chief Counsel Daniel Troy said

GPhA Objection To Generic Drug Rule Could Backfire, FDA Counsel Troy Warns

The generic industry should consider carefully any attempt to derail FDA's regulatory approach to Waxman/Hatch reform, agency Chief Counsel Daniel Troy told the Generic Pharmaceutical Association

Related Content

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel